D.B. Root & Company LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 7.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,519 shares of the biopharmaceutical company’s stock after selling 385 shares during the quarter. D.B. Root & Company LLC’s holdings in Pfizer were worth $232,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of PFE. Front Street Capital Management Inc. grew its holdings in Pfizer by 4.3% in the 1st quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock valued at $268,000 after buying an additional 215 shares in the last quarter. Lindenwold Advisors raised its stake in Pfizer by 1.0% during the third quarter. Lindenwold Advisors now owns 21,151 shares of the biopharmaceutical company’s stock worth $926,000 after purchasing an additional 216 shares during the period. SRS Capital Advisors Inc. grew its stake in shares of Pfizer by 1.6% in the 2nd quarter. SRS Capital Advisors Inc. now owns 13,618 shares of the biopharmaceutical company’s stock valued at $714,000 after buying an additional 218 shares during the period. Signet Financial Management LLC increased its holdings in shares of Pfizer by 0.6% during the 3rd quarter. Signet Financial Management LLC now owns 34,338 shares of the biopharmaceutical company’s stock worth $1,503,000 after buying an additional 220 shares during the last quarter. Finally, Mitchell Mcleod Pugh & Williams Inc. lifted its holdings in Pfizer by 0.7% in the third quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 33,978 shares of the biopharmaceutical company’s stock valued at $1,487,000 after acquiring an additional 222 shares during the last quarter. Institutional investors and hedge funds own 67.62% of the company’s stock.
Wall Street Analyst Weigh In
A number of research firms have commented on PFE. The Goldman Sachs Group raised shares of Pfizer from a “neutral” rating to a “buy” rating and upped their target price for the company from $47.00 to $60.00 in a research report on Tuesday, December 13th. SVB Leerink reduced their price target on shares of Pfizer from $49.00 to $48.00 and set a “market perform” rating on the stock in a research report on Wednesday, February 1st. Morgan Stanley cut their target price on shares of Pfizer from $53.00 to $45.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 1st. Cantor Fitzgerald reissued an “overweight” rating and issued a $75.00 price target on shares of Pfizer in a research report on Wednesday, February 1st. Finally, StockNews.com assumed coverage on Pfizer in a research note on Thursday, March 16th. They issued a “buy” rating on the stock. Eight analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $49.93.
Pfizer Price Performance
Pfizer (NYSE:PFE – Get Rating) last released its earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.03 by $0.11. The business had revenue of $24.30 billion for the quarter, compared to analyst estimates of $24.40 billion. Pfizer had a return on equity of 42.03% and a net margin of 31.27%. The company’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 earnings per share. On average, analysts predict that Pfizer Inc. will post 3.3 EPS for the current year.
Insider Buying and Selling
In other Pfizer news, major shareholder Pfizer Inc purchased 1,811,594 shares of the firm’s stock in a transaction that occurred on Friday, March 17th. The shares were purchased at an average cost of $2.76 per share, for a total transaction of $4,999,999.44. Following the completion of the purchase, the insider now directly owns 5,952,263 shares in the company, valued at $16,428,245.88. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.05% of the stock is currently owned by corporate insiders.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
Featured Articles
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- MarketBeat Week in Review – 4/3 – 4/7
- Costco Sales Disappoint, Markets Are Missing This Upside Driver
- First Republic Bank Is A Speculative Play, Here’s Why
- The WD-40 Company Bottoms With Reversal In Sight
- 3 Low-Cost Stock ETFs That Are Crushing It This Year
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
